- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06055023
Study of Tolerability, Safety, and Pharmacokinetics of ZL-82 in Healthy Adult Subjects.
Phase I Clinical Study on the Tolerability, Safety and Pharmacokinetics of Single-dose Dose Escalation and Multiple-dose Oral ZL-82 Tablets in Healthy Adult Subjects
ZL-82 is an oral janus kinase (JAK) inhibitor. In vitro biological mass spectrometry identification test proves that ZL-82 can selectively and irreversibly inhibit JAK3. It has obvious safety advantages, with a wide therapeutic window and controllable cardiotoxicity. This is also demonstrated from preliminary GLP-conditions of acute toxicity in SD rats and Beagle dogs. Results of 4-week long-term toxicity in Beagle dogs also support this notion. Therefore, ZL-82 has the potential to treat rheumatoid arthritis. It Used to relieve and heal swelling, pain, stiffness, and limited mobility that may be caused by rheumatoid arthritis.The drug is intended to be used in patients with RA to relieve and heal swelling, pain, stiffness, and limited mobility that may be caused by rheumatoid arthritis.
Pharmacodynamic studies show that ZL-82 has a strong inhibitory effect on JAK3 with IC50 of 2.8 nM, and has no obvious inhibitory effect on JAK1, JAK2 and TYK2. Compared with the similar drug Tofacitinib, its inhibitory effect on JAK3 subtype is 1nM, but its inhibition IC50 for JAK1 subtype and JAK2 subtype are 112nM and 20nM, respectively.and its selectivity is 100-fold and 20-fold, respectively.Also, the selectivity multiples of ZL-82 were 100-fold and 20-fold than tofacitinib , respectively, which indicates that ZL-82 is more selective than the marketed Tofacitinib.This allows ZL-82 to precisely inhibit JAK kinase and block a series of cytokines in the downstream signaling pathway. And show significant effect on rheumatoid arthritis.
The experimental results showed that in DTH and CIA models, 25, 50, 75, and 100 mg/kg of this variety could dose-dependently inhibit joint swelling in mice.
Objectives of Study
Main Purpose:
- To evaluate the tolerability, safety and pharmacokinetic characteristics of a single oral dose of ZL-82 tablets in healthy adult subjects;
- To explore the effect of eating on the PK of oral ZL-82 tablets in healthy adult subjects;
- To evaluate the tolerability, safety and pharmacokinetics of ZL-82 tablets after multiple oral administration in healthy adult subjects.
Study Overview
Status
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Sun Liangkun, bachelor
- Phone Number: 15885742617
- Email: bailing_stt@126.com
Study Contact Backup
- Name: Wu Dan, master
- Phone Number: 13027889075
- Email: 443740238@qq.com
Study Locations
-
-
GuiYang
-
Guizhou, GuiYang, China
- Recruiting
- Affiliated Hospital of Guizhou Medical University
-
Contact:
- Yan He, DOCTOR
- Phone Number: 18984058185
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy subjects, regardless of gender, 18 to 45 years old (including 18 and 45 years old)
- The weighing of male subjects ≥ 50kg, female subjects ≥ 45kg, and a body mass index (BMI) between 19 and 25kg/m2 (including boundary values)
- The medical history, physical examination, laboratory examination items and various tests and tests related to the trial before enrollment were normal or abnormal without clinical significance, and the clinical research doctor judged that they were qualified.
- Be able to understand the informed consent form, voluntarily participate in the trial and sign the informed consent form
Exclusion Criteria:
- Allergic constitution, such as those who are known to be allergic to two or more substances, or those who are known to be allergic to JAK inhibitors or to the excipients contained in the test drug
- ALT and/or AST>1×ULN, TIB>1×ULN, GGT>1×ULN; Scr>1×ULN
- Major surgery within the 3 months prior to the trial or planning to undergo surgery during the trial
- Acute illness within 2 weeks prior to trial
- Have any serious diseases such as cardiovascular system, digestive system, urinary system, respiratory system, nervous system, immune system, endocrine system, malignant tumor, mental illness, etc.
- History of dysphagia or any gastrointestinal disease (or gastrointestinal resection, etc.) affecting drug absorption
- HIV antibody, Treponema pallidum antibody, hepatitis B surface antigen and hepatitis C antibody test are positive
- Positive urine drug screen (including morphine, methamphetamine, ketamine, MDMA, THC)
- Systolic blood pressure>140mmHg or diastolic blood pressure>90mmHg during the screening period;
- Blood donation or blood loss ≥400mL within 3 months, or blood transfusion; blood donation or blood loss ≥200mL within 1 month;
- Have special requirements for diet or cannot comply with the unified diet and corresponding regulations of the research center
- Alcoholics (alcoholism refers to drinking 60-degree white wine ≥10.5L or red wine ≥3.5L per week for more than 5 years), drinking a lot of coffee-containing beverages (more than 8 cups per day, 1 cup = 250ml) or heavy smoking (average > 20 sticks/day);
- Have used any prescription drugs (JAK inhibitors, etc.) that may have an effect on the test drug within 2 weeks;
- 4 weeks (28 days) before enrollment, strong inducers of liver metabolic enzymes was limit. ( such as omeprazole, barbiturates, carbamazepine, aminoglutamine, griseofulvin, carbamazepine, Phenytoin, Gluter, Rifampicin, Sulfinpyrazone, Roxithromycin, etc. )
- Participate in clinical trials of other drugs or medical devices as subjects within 3 months
- Women who are pregnant or breastfeeding or women of childbearing age who have had unprotected sex with their partner within 14 days before the test;
- The subjects or their partners are unwilling to use non-drug contraceptive measures (such as total abstinence, condoms, IUDs, ligation, etc.) for contraception during the trial, or the subject and his partner has a pregnancy plan within 6 months of signing the informed consent;
- Not suitable to participate in the trial according to the judgment of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ZL-82 12.5mg
2 case,The starting dose,Take the medicine once on D1 ,D1 through 7.
|
1 case,The starting dose,Take the medicine once on D1,D1-7.
|
Experimental: ZL-82 25mg
8 case,The starting dose,Take the medicine once on D1 ,D1 through 7.
|
1 case,The starting dose,Take the medicine once on D1,D1-7.
|
Experimental: ZL-82 50mg
8 case,The starting dose,Take the medicine once on D1 ,D1 through 7.
|
1 case,The starting dose,Take the medicine once on D1,D1-7.
|
Experimental: ZL-82 100mg
8 case,The starting dose,Take the medicine once on D1 ,D1 through 7.
|
1 case,The starting dose,Take the medicine once on D1,D1-7.
|
Experimental: ZL-82 200mg
8 case,The starting dose,Take the medicine once on D1 ,D1 through 7.
|
1 case,The starting dose,Take the medicine once on D1,D1-7.
|
Experimental: ZL-82 300mg
8 case,The starting dose,Take the medicine once on D1 ,D1 through 7.
|
1 case,The starting dose,Take the medicine once on D1,D1-7.
|
Experimental: ZL-82 450mg
8 case,The starting dose,Take the medicine once on D1 ,D1 through 7.
|
1 case,The starting dose,Take the medicine once on D1,D1-7.
|
Experimental: ZL-82 600mg
8 case,The starting dose,Take the medicine once on D1 ,D1 through 7.
|
1 case,The starting dose,Take the medicine once on D1,D1-7.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK) of ZL-82:Cmax
Time Frame: 24hours
|
Estimation of maximum observed plasma concentration
|
24hours
|
Pharmacokinetics (PK) of ZL-82:Tmax
Time Frame: 24hours
|
Estimation of time to reach Cmax
|
24hours
|
Pharmacokinetics (PK) of ZL-82:AUC0-24h
Time Frame: 24hours
|
Estimation of AUC from time zero to the last measured time point
|
24hours
|
Pharmacokinetics (PK) of ZL-82:AUC0-∞
Time Frame: 24hours
|
Estimation of AUC from time zero extrapolated to infinity
|
24hours
|
Pharmacokinetics (PK) of ZL-82:Vd
Time Frame: 24hours
|
Estimation of apparent volume of distribution
|
24hours
|
Pharmacokinetics (PK) of ZL-82:t1/2
Time Frame: 24hours
|
Estimation of terminal elimination half-life
|
24hours
|
Pharmacokinetics (PK) of ZL-82:CLz/F
Time Frame: 24hours
|
Estimation of clearance when dosed orally
|
24hours
|
Pharmacokinetics (PK) of ZL-82:Vz/F
Time Frame: 24hours
|
Estimation of apparent volume of distribution when dosed orally
|
24hours
|
Pharmacokinetics (PK) of ZL-82:Kel
Time Frame: 24hours
|
Estimation of the elimination rate constant of a drug in the body
|
24hours
|
Collaborators and Investigators
Investigators
- Study Chair: Chen Lijuan, doctor, West China Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-ZL82-PI-I
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis (RA)
-
SinoMab BioScience LtdRecruitingRheumatoid Arthritis(RA)China
-
Veena Ranganath, MD, MSRecruiting
-
Astellas Pharma China, Inc.CompletedRheumatoid Arthritis (RA)China, Korea, Republic of, Taiwan
-
AbbVieActive, not recruitingRheumatoid Arthritis (RA)Argentina, Australia, Austria, Belgium, France, Germany, Greece, Ireland, Israel, Italy, Kuwait, Mexico, Russian Federation, Saudi Arabia, Spain, Switzerland, Taiwan, United Arab Emirates, Uruguay
-
Jiangsu HengRui Medicine Co., Ltd.CompletedRheumatoid Arthritis (RA)China
-
Faiq GorialCompleted
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Bristol-Myers SquibbUnknown
-
medac GmbHPPDCompletedRheumatoid Arthritis (RA)United States
-
Antares Pharma Inc.CompletedRheumatoid Arthritis (RA)United States
-
Chugai Pharma TaiwanCompletedRheumatoid Arthritis (RA)Taiwan
Clinical Trials on ZL-82 12.5mg
-
Zai Lab Pty. Ltd.UnknownChronic Obstructive Pulmonary Disease | Asthma | Idiopathic Pulmonary FibrosisAustralia
-
Zai Lab (Shanghai) Co., Ltd.Zai Lab (US) LLCRecruiting
-
Zai Biopharmaceutical (Suzhou) Co., Ltd.Recruiting
-
Zai Lab (Shanghai) Co., Ltd.Completed
-
Zai Lab Pty. Ltd.Completed
-
Oncotartis, Inc.UnknownLymphoma | Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Lymphoma, T-Cell | Lymphoma, Hodgkin | Lymphoma, Peripheral T-CellUnited States
-
Prism Pharma Co., Ltd.CompletedSystemic SclerodermaUnited States
-
TyrogenexCompleted
-
Bracco Diagnostics, IncCompletedRadiation ExposureUnited States
-
Bracco Diagnostics, IncCompletedRadiation ExposureUnited States